Fungal infections have emerged as a significant and potentially lethal complication in critically ill patients with Covid-19. Infections caused by Aspergillus, Candida, and Mucormycetes, are a common cause of morbidity and mortality in critically ill patients, especially those with preexisting comorbidities. The underlying mechanisms that predispose fungal infections are not fully understood, but the use of corticosteroids, underlying conditions, prolonged hospitalization, and antibiotic are several factors that might be associated. They are associated with higher mortality rates, increased healthcare costs, delayed recovery, and prolonged hospitalization. Antifungal therapy for COVID-19-associated fungal infections can interact with other drugs used to treat COVID-19, which can complicate management. The emergence of antifungal resistance is a concern for the management of COVID-19-associated fungal infections.
Key words: Pulmonary aspergillosis, invasive candidiasis, mucormycosis, coronavirus, antifungal agents.
|
